hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
=== Studying cold traps on airless bodies === As these shadows receive no insolation, most of the heat they receive comes from scattered and emitted radiation from the surrounding topography. Usually, horizontal heat conduction from adjacent warmer areas can be neglected because of the high porosity and therefore low thermal conductivity of the uppermost layers of airless bodies. Consequently, the temperatures of these permanent shadows can be modeled using ray-casting or ray-tracing algorithms coupled with 1D vertical heat conduction models. In some cases, such as bowl-shaped craters, it is possible to obtain an expression for the equilibrium temperature of these shadows. Additionally, the temperatures (and therefore the stability) of cold traps can be remotely sensed by an orbiter. The temperatures of lunar cold traps have been extensively studied by the Lunar Reconnaissance Orbiter's Diviner radiometer. On Mercury, evidence for ice deposits inside cold traps has been obtained through radar, reflectance, and visible imagery. On Ceres, cold traps have been detected by the Dawn spacecraft.
=== EC 2.3.2: Aminoacyltransferases === EC 2.3.2.1: D-glutamyltransferase EC 2.3.2.2: γ-glutamyltransferase EC 2.3.2.3: lysyltransferase EC 2.3.2.4: Now classified as EC 4.3.2.9, γ-glutamylcyclotransferase EC 2.3.2.5: glutaminyl-peptide cyclotransferase EC 2.3.2.6: leucyltransferase EC 2.3.2.7: aspartyltransferase EC 2.3.2.8: arginyltransferase EC 2.3.2.9: agaritine γ-glutamyltransferase EC 2.3.2.10: UDP-N-acetylmuramoylpentapeptide-lysine N6-alanyltransferase EC 2.3.2.11: alanylphosphatidylglycerol synthase EC 2.3.2.12: peptidyltransferase EC 2.3.2.13: protein-glutamine g-glutamyltransferase EC 2.3.2.14: D-alanine γ-glutamyltransferase EC 2.3.2.15: glutathione γ-glutamylcysteinyltransferase EC 2.3.2.16: lipid II:glycine glycyltransferase EC 2.3.2.17: N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-(N6-glycyl)-D-alanyl-D-alanine-diphosphoundecaprenyl-N-acetylglucosamine:glycine glycyltransferase EC 2.3.2.18: N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-(N6-triglycine)-D-alanyl-D-alanine-diphosphoundecaprenyl-N-acetylglucosamine:glycine glycyltransferase EC 2.3.2.19: ribostamycin:4-(γ-L-glutamylamino)-(S)-2-hydroxybutanoyl-[BtrI acyl-carrier protein] 4-(γ-L-glutamylamino)-(S)-2-hydroxybutanoate transferase EC 2.3.2.20: cyclo(L-leucyl-L-phenylalanyl) synthase EC 2.3.2.21: cyclo(L-tyrosyl-L-tyrosyl) synthase EC 2.3.2.22: cyclo(L-leucyl-L-leucyl) synthase EC 2.3.2.23: E2 ubiquitin-conjugating enzyme EC 2.3.2.24: (E3-independent) E2 ubiquitin-conjugating enzyme EC 2.3.2.25: N-terminal E2 ubiquitin-conjugating enzyme EC 2.3.2.26: HECT-type E3 ubiquitin transferase EC 2.3.2.27: RING-type E3 ubiquitin transferase EC 2.3.2.28: L-allo-isoleucyltransferase EC 2.3.2.29: aspartate/glutamate leucyltransferase EC 2.3.2.30: L-ornithine Nα-acyltransferase EC 2.3.2.31: RBR-type E3 ubiquitin transferase EC 2.3.2.32: cullin-RING-type E3 NEDD8 transferase EC 2.3.2.33: RCR-type E3 ubiquitin transferase EC 2.3.2.34: E2 NEDD8-conjugating enzyme EC 2.3.2.35: capsaicin synthase EC 2.3.2.36: RING-type E3 ubiquitin transferase (cysteine targeting)
=== CaMK2A === CaMKIIA is one of the major forms of CamKII. It has been found to play a critical role in sustaining activation of CamKII at the postsynaptic density. Studies have found that knockout mice without CaMKIIA demonstrate a low frequency of LTP. Additionally, these mice do not form persistent, stable place cells in the hippocampus.
== Further reading == Chemically synthesized genes for human insulin Synthesis of customized petroleum-replica fuel molecules by targeted modification of free fatty acid pools in Escherichia coli Metabolic engineering of Saccharomyces cerevisiae for production of fatty acid short- and branched-chain alkyl esters biodiesel Ginkgo Bioworks featured work
== History == Fabio Cavalli founded the business in 2001 with his wife Vera and two partners. The company initially operated privately; the holding company was established in March 2007. In July 2010, Ruggero Gramatica succeeded Cavalli as chief executive, while Cavalli became executive chairman. Cavalli did not stand for re-election to the board in May 2011.
Sources: en.wikipedia.org
Type I : Extra-dural; no nerve roots or rootlets such as intra-sacral meningoceles; probably of congenital origin developing from the dural sac to which they are connected by a little collar. They are found at the point of exit of a dorsal nerve root from the dural sac. They are sometimes difficult to identify and can be "seen" as a type II cyst on imaging. These cysts are often associated with foramina enlargement and scalloping of the vertebrae. It is very important to distinguish them from sacral meningoceles going to the pelvic area; they are often associated with other congenital abnormalities (teratomes, dermoïdes, lipomas, and other abnormalities(uro-genital and ano-rectal)) Type II: Extra-dural; nerve root present (such as Tarlov or perineural cysts). There are often not only one but multiple cysts, mostly found in the sacrum area. There are two types: Tarlov (perineural) cysts are located posteriorly to the root ganglion, with nerve fibres inside or nerve tissue in the walls; they are not communicating with the perineural arachnoid space. Type-II cysts are very small in the upper sacral area, but can be bigger (up to 3 centimetres or 1.2 inches) if found located in the lower part of the sacrum. The second variant of type-II cysts are called "meningeal diverticula". They are located anteriorly to the nerve root ganglion, with nerves fibres inside and communicating with the subarachnoid space. Type III: intra-dural; these are either congenital or caused by trauma; they are rarely associated with other abnormalities and rare in occurrence.
== See also == Dimethylaminoethylindole Dimethyltryptamine/harmine Dimethyltryptamine/β-carbolines List of psychoactive plants List of substances used in rituals Psychedelic replication Substituted tryptamine
=== Tumor suppression === It has also been proven to be a tumor suppressor for some tumors. It probably is aided by its action in upregulating thrombospondin, SPARC (osteonectin), and fibronectin. However it has also been speculated to aid in extravasation in circulating melanoma cells. In case of prostate cancer it has been shown to be expressed in cancer associated stroma but not in normal stroma and has been suggested to be of potential help for cancer specific drug targeting [1].
ASQ provides its members with certification, training, publications, conferences, and other services. ASQ is a founding partner of the American Customer Satisfaction Index (ACSI), a quarterly economic indicator. Since 1989, ASQ has administered the annual Malcolm Baldrige National Quality Award. The ASQ also gives the Dorian Shainin Medal, which is awarded annually for the "Development and Application of Creative or Unique Statistical Approaches in the Solving of Problems Relative to the Quality of Product or Service".
Sources: en.wikipedia.org
2-Arachidonoylglycerol (2-AG) is an endocannabinoid, an endogenous agonist of the CB1 receptor and the primary endogenous ligand for the CB2 receptor. It is an ester formed from the omega-6 fatty acid arachidonic acid and glycerol. It is present at relatively high levels in the central nervous system, with cannabinoid neuromodulatory effects. It has been found in bovine and human milk. The chemical was first described in 1994–1995, although it had been discovered some time before that. The activities of phospholipase C (PLC) and diacylglycerol lipase (DAGL) mediate its formation. 2-AG is synthesized from arachidonic acid-containing diacylglycerol (DAG). 2-AG, unlike anandamide (another endocannabinoid), is present at relatively high levels in the central nervous system; it is the most abundant molecular species of monoacylglycerol found in mouse and rat brain (~5–10 nmol/g tissue). Detection of 2-AG in brain tissue is complicated by the relative ease of its isomerization to 1-AG during standard lipid extraction conditions. It has been found in bovine as well as human milk.
The reaction 239Pu+48Ca has also been suggested as a means to produce 282Fl and 283Fl in the 5n and 4n channels respectively, but so far only the 3n channel leading to 284Fl has been observed. The Dubna team repeated their investigation of the 240Pu+48Ca reaction in 2017, observing three new consistent decay chains of 285Fl, another decay chain from this nuclide that may pass through some isomeric states in its daughters, a chain that could be assigned to 287Fl (likely from 242Pu impurities in the target), and some spontaneous fissions of which some could be from 284Fl, though other interpretations including side reactions involving evaporation of charged particles are also possible. The alpha decay of 284Fl to spontaneously fissioning 280Cn was finally observed by the Dubna team in 2024.
Upon learning it was Tetsu, Baachiyo attempts to force himself on the officer before the Dekarangers arrest the alien. Baachiyo is voiced by Motomu Kiyokawa (清川元夢, Kiyokawa Motomu) in his immature form and Taiki Matsuno (松野 太紀, Matsuno Taiki) in his adult form. Spiritian Byoi (スピリト星人ビョーイ, Supirito Seijin Byōi): A gas-based criminal from Planet Spirit who is capable of possessing other beings. He secretly possesses Ban, but is forced out by Hakutaku. Byoi retaliates by piloting a cyclops-themed flight-capable Kaijuki called Hunter Jet (ハンタージェット, Hantā Jetto), but is deleted by Deka Bike Robo. Byoi is voiced by Katsumi Shiono. Beesian Beeling (ビース星人ビーリング, Bīsu Seijin Bīringu): A lizard-themed fighter, from Planet Bees, in Durden's illegal fight club who consumes the illegal steroid Megagesterine and fights Hoji and Tetsu. Beeling is voiced by Yoshimitsu Shimoyama (下山 吉光, Shimoyama Yoshimitsu). Barigean Milibar (バリゲ星人ミリバル, Barige Seijin Miribaru): A aerokinetic cycloptic thief and serial killer from Planet Barige who previously robbed criminals to raise money for orphans before he became reckless. He enlarges himself, but is deleted by Super Dekaranger Robo. During the events of the crossover film Tokusou Sentai Dekaranger vs. Abaranger, Saunaginnan resurrects Milibar, who is subsequently killed by Deka Red, Blue, and Green, and Abare Yellow. Milibar is voiced by Masaru Ōbayashi (大林 勝, Ōbayashi Masaru), who also portrays his human form.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.